[{"Assets_0_Q2_USD":911158000.0,"CommonStockSharesOutstanding_0_Q2_shares":297892180.0,"EarningsPerShareBasic_1_Q2_USD":0.29,"EarningsPerShareBasic_2_Q2_USD":0.68,"EarningsPerShareDiluted_1_Q2_USD":0.28,"EarningsPerShareDiluted_2_Q2_USD":0.65,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":146577000.0,"NetIncomeLoss_1_Q2_USD":87494000.0,"NetIncomeLoss_2_Q2_USD":203351000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":312241000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":313024000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":297336000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":296874000.0,"Ticker":"EXEL","CIK":"939767","name":"EXELIXIS, INC.","OfficialName":"Exelixis Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"7287350058.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20180801"}]